Efficacy of Human Adipose Derived Mesenchymal Stem Cells in Promoting Skin Wound Healing

Abstract

Background. The aim of this pilot clinical study is to evaluate the efficacy of human adipose derived mesenchymal stem cells (HAMSCs) treatment for the wound healing with patients. Methods. This study was a clinical trial to investigate the efficacy of human adipose derived mesenchymal stem cells treatment for the wound healing with patients. 346 patients with skin wounds attending the central hospital of Yue Yang were enrolled in the study, setting in the period from January 2016 to January 2021. Patients were randomly allocated into two groups: experimental group received treatment with human adipose derived mesenchymal stem cells for each 10 cm2 of wound and control group received conventional dressing with normal saline for each 10 cm2 of wound. Results. No adverse events were recorded during the period of treatment. The granulation tissue coverage rate and thickness of granulation tissue after 10 days of treatment in experimental group were significantly improved compared with control group. Furthermore, the occurrence of bleeding of wound and suppurative wounds between two groups had significant difference ( P < 0.05 ). Conclusion. The data in this pilot study indicated that human adipose derived mesenchymal stem cells may be a safe and effective alternative therapy for wound healing. Moreover, larger, placebo-controlled, perspective studies are necessity to evaluate the efficacy and safety of human adipose derived mesenchymal stem cells treatment for wound healing patients.

Principais evidências clínicas da terapia com células-tronco na cicatrização de queimaduras: uma revisão sistemática

“…À luz dos resultados, verificou-se que a terapia com células-tronco melhorou significativamente a taxa de cicatrização de queimaduras, independentemente do tipo de transplante, área da queimadura e método de tratamento (Rasulov et al, 2005;Mansilla et al, 2015;Zinovyev et al, 2018;Zhou et al, 2022).…”

“…Dois tipos de células-tronco foram utilizados nos estudos: células-tronco derivadas da medula óssea (BMSC) (Rasulov et al, 2005;Mansilla et al, 2015); células-tronco derivadas do tecido adiposo (ASC) (Zinovyev et al, 2018;Zhou et al, 2022). As BMSC eram tradicionalmente a principal fonte de células-tronco mesenquimais adultas, porém sua coleta era Research, Society and Development, v. 11, n. 10, e184111032781, 2022 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v11i10.32781 invasiva com baixos rendimentos.…”

“…Além disso, os tecidos adiposos produzem hormônios como a leptina, que auxiliam na regeneração da ferida. Todas essas influências promovem a regeneração por meio de mecanismos de imunomodulação, neoangiogênese e reparo endógeno (Zhou et al, 2022). Isto pode explicar o fato de os estudos clínicos mais recentes terem utilizados células-tronco do tipo ASC e terem obtidos resultados mais satisfatórios.…”

Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review

“…Promoted bone architecture N/A [ 129 ] Mandibular lesions Intralesional 20 N/A BMSC N/A No Increase in bone density with respect to the baseline levels. The percent of reduction in the defects’ size was significantly higher compared with control N/A [ 130 ] Wound healing Intralesional 8 1 × 10 6 cell BMSC N/A No Reduction in ulcer size or complete wound closure N/A [ 131 ] Wound healing N/A 316 N/A Adipose MSC N/A No Granulation tissue coverage rate and thickness of granulation tissue were significantly improved N/A [ 132 ] Diabetic foot ulcers N/A 59 1 × 10 6 cells Adipose MSC N/A No Complete wound closure was achieved for 82% at week 12. Kaplan–Meier median times to complete closure were reduced NCT02619877 [ 133 ] Diabetic foot ulcers Endovascular 53 4.8 to 8.6 × 10 7 cell UC-MSC N/A No Significant increase in neovessels, accompanied by complete or gradual ulcer healing N/A [ …”

“…No adverse events were noted. In a study by Zhou et al, 346 patients with skin wounds were administered adipose MSCs [ 132 ]. There were no adverse events during the trial.…”